ArticleEuropean journal of clinical pharmacology2023

A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease.

Christina Lourdes Mayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.